Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 114, Issue 32, Pages 8631-8636Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1708106114
Keywords
Alzheimer's disease; amyloid-beta; BACE inhibition; in vivo calcium imaging; neural circuit dysfunction
Categories
Funding
- European Research Council
- European Union
- German Research Foundation (Integrated Research Training Group 1373)
- German Research Foundation (Collaborative Research Center 870)
- Alzheimer Forschung Initiative
Ask authors/readers for more resources
Amyloid-beta (A beta) is thought to play an essential pathogenic role in Alzheimer's disease (AD). A key enzyme involved in the generation of A beta is the beta-secretase BACE, for which powerful inhibitors have been developed and are currently in use in human clinical trials. However, although BACE inhibition can reduce cerebral A beta levels, whether it also can ameliorate neural circuit and memory impairments remains unclear. Using histochemistry, in vivo Ca2+ imaging, and behavioral analyses in a mouse model of AD, we demonstrate that along with reducing prefibrillary A beta surrounding plaques, the inhibition of BACE activity can rescue neuronal hyperactivity, impaired long-range circuit function, and memory defects. The functional neuronal impairments reappeared after infusion of soluble A beta, mechanistically linking A beta pathology to neuronal and cognitive dysfunction. These data highlight the potential benefits of BACE inhibition for the effective treatment of a wide range of AD-like pathophysiological and cognitive impairments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available